Press release
Neuroblastoma Market Demonstrates Long-Term Growth Potential At 5.5% CAGR
Neuroblastoma Market
Forecasted Expansion of the Neuroblastoma Market Size by 2030
The neuroblastoma market is anticipated to reach $4.12 billion by 2030, expanding at a compound annual growth rate (CAGR) of 5.5%. This growth is fueled by several factors, including increased research in targeted therapies, stronger investments in cell therapy products, broader adoption of precision oncology approaches, and the development of novel pediatric immunotherapy treatments. Enhanced diagnostic imaging technologies that support early detection are also playing a pivotal role in driving demand. Key trends shaping the market include a rising preference for immunotherapy vaccines aimed at pediatric cancers, growing use of targeted oral chemotherapy tablets, ongoing development of monoclonal antibody therapies, advancements in cell therapy and regenerative oncology, alongside a heightened emphasis on early diagnosis and effective symptom management.
The neuroblastoma market size has grown strongly in recent years. It will grow from $3.14 billion in 2025 to $3.32 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increased prevalence of pediatric neuroblastoma cases, early adoption of chemotherapy treatments, development of immunotherapy vaccines, growth in clinical diagnosis capabilities, rising awareness of childhood cancer symptoms.
Download a free sample of the neuroblastoma market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20901&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR
Leading Companies Dominating the Neuroblastoma Sector
The neuroblastoma market features numerous significant players, including Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sartorius AG, Recordati S.p.A, United Therapeutics Corporation, BeiGene Ltd., MacroGenics Inc., Y-mAbs Therapeutics Inc., RedHill Biopharma Ltd., Clarity Pharmaceuticals Ltd., EUSA Pharma (UK) Ltd., US WorldMeds LLC, Ascentage Pharma, Laboratorio Elea Phoenix S.A, Curis Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd., Essential Pharma S.A, Cellectar Biosciences Inc., and Provectus Biopharmaceuticals Inc.
In a notable recent development, Ligand Pharmaceuticals Inc., a US-based biopharmaceutical company, completed the acquisition of Apeiron Biologics AG for $100 million in September 2024. This deal provides Ligand with royalty rights to Qarziba, enhancing its commercial royalty portfolio with a high-value immunotherapy targeting high-risk neuroblastoma. Apeiron Biologics AG, headquartered in Austria, specializes in developing immunotherapeutic solutions for neuroblastoma, and this acquisition helps Ligand secure long-term, stable revenue streams from diversified product offerings.
Emerging Future Trends within the Neuroblastoma Market
Forward-looking companies in this sector are concentrating on innovative treatments such as humanized anti-GD2 monoclonal antibodies, which are designed to selectively target cancer cells with improved safety and reduced immune rejection. These antibodies include human components to minimize adverse immune responses while effectively attacking the GD2 molecule present on neuroblastoma cells.
For example, in August 2023, Renaissance Pharma Ltd., a UK-based clinical-stage pharmaceutical firm, secured exclusive rights to develop, manufacture, and commercialize Hu14.18K322A (Hu14.18), a humanized anti-GD2 antibody licensed from St. Jude Children's Research Hospital. This therapy targets newly diagnosed high-risk neuroblastoma, a rare and aggressive childhood cancer. The agreement covers key global markets such as the United States, Canada, Europe, China, Japan, and Turkey, underscoring the growing international focus on advanced neuroblastoma treatments.
View the full neuroblastoma market report:
https://www.thebusinessresearchcompany.com/report/neuroblastoma-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR
Detailed Segmentation of the Global Neuroblastoma Market
This report segments the neuroblastoma market into the following categories:
1) By Product Type: Tablets, Vaccines, Other Product Types
2) By Treatment Type: Chemotherapy, Immunotherapy, Other Treatment Types
3) By Distribution Channel: Online, Offline
4) By End-User: Hospitals, Clinics
Additional subcategories include:
- Tablets: Oral Chemotherapy Tablets and Targeted Therapy Tablets
- Vaccines: Immunotherapy Vaccines and Therapeutic Vaccines
- Other Product Types: Injectable Drugs, Monoclonal Antibodies, and Cell Therapy Products
Together, these segments provide a comprehensive view of the market's structure and the diverse therapeutic options available to combat neuroblastoma globally.
Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neuroblastoma Market Demonstrates Long-Term Growth Potential At 5.5% CAGR here
News-ID: 4611314 • Views: …
More Releases from The Business Research Company
Neurofeedback Market Study Explores Industry Growth Toward $2.59 Billion
The neurofeedback market is steadily gaining traction as mental health awareness and personalized treatment options continue to evolve. Driven by technological advancements and growing adoption of digital health solutions, this sector is set to witness significant expansion over the coming years. Here is a detailed breakdown of the market size, key players, emerging trends, and segmentation that define the future landscape of the neurofeedback industry.
Expected Market Growth and Expansion of…
Neurodiagnostics Market Research Reveals Path To $13.47 Billion By 2030
The neurodiagnostics sector is rapidly evolving, driven by technological innovations and rising demand for early and accurate neurological assessments. This industry plays a crucial role in diagnosing and monitoring neurological conditions, and its growth is set to accelerate in the coming years. Let's explore the market size projections, leading players, key trends, and segmentation that define this dynamic field.
Projected Market Size and Growth Outlook for the Neurodiagnostics Industry
The…
Netherton Syndrome Market Outlook Signals Expansion To $2.01 Billion Through 203 …
The market for Netherton syndrome treatments is gaining significant attention as advancements in dermatology and biotechnology continue to evolve. With increasing investments in innovative therapies and diagnostic tools, this niche sector is set to experience substantial growth and transformation over the coming years. Let's explore the projected market size, key players, emerging trends, and segment classifications shaping the future of Netherton syndrome management.
Projected Market Valuation and Growth of the Netherton…
Nephrotic Syndrome Market Report 2026 Market Outlook Supported By A Forecast 10. …
Exploring the future outlook of the nephrotic syndrome industry reveals promising growth fueled by medical advancements and evolving treatment approaches. The market is set to expand significantly over the next several years as technology and personalized care gain momentum. Let's examine the current market value projections, key players driving innovation, notable industry trends, and important segments shaping this sector.
Forecasted Market Size and Growth of the Nephrotic Syndrome Industry
The…
More Releases for Neuroblastoma
Leading Companies Reinforcing Their Presence in the Neuroblastoma Market
The neuroblastoma sector is on a steady path of growth, driven by significant advancements in treatment and diagnostic technologies. As research intensifies and new therapies emerge, this market is set to transform the landscape of pediatric cancer care. Let's explore the current market size, key players, prevailing trends, and segment outlooks shaping the neuroblastoma industry.
Neuroblastoma Market Size Looking Ahead to 2030
The neuroblastoma market is projected to expand considerably, expected…
Pediatric Relapsed & Refractory Neuroblastoma Market Trades 2034
Market Overview
The Pediatric Relapsed and Refractory Neuroblastoma Market is expanding as unmet needs remain high for children who fail first-line therapy or experience disease recurrence. Neuroblastoma, a rare pediatric cancer originating in nerve tissues, poses significant treatment challenges when it becomes resistant or relapses after conventional chemotherapy, surgery, and radiation. As a result, demand for novel immunotherapies, targeted biologics, CAR-T therapies, and precision medicine is accelerating globally. Improved survival outcomes,…
Neuroblastoma Market Massive Growth opportunity Ahead
Neuroblastoma market Size, Status, and Forecast for the 2025-2034. In-depth research has been compiled to provide the most up-to-date information on key aspects of the worldwide market. This research report covers major aspects of the Neuroblastoma Market including drivers, restraints, historical and current trends, regulatory scenarios, and technological advancements. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The…
Pediatric Neuroblastoma Treatment Market - Redefining Possibilities: Advancement …
Newark, New Castle, USA: The "Pediatric Neuroblastoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Pediatric Neuroblastoma Treatment Market: https://www.growthplusreports.com/report/pediatric-neuroblastoma-treatment-market/7681
This latest report researches the industry structure,…
Neuroblastoma Drugs Market Size, Share, Development by 2024
New report published by Global Info Research which offers insights on the Global Neuroblastoma Drugs market.
Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently starts from one of the adrenal glands, but can also develop in the neck, chest, abdomen, or spine. Symptoms may include bone pain, a lump in the abdomen, neck, or chest, or a painless bluish lump under…
Global Neuroblastoma Treatment Market: Latest Trends and Insights 2023
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants…
